Related Experiment Video
Updated: Apr 26, 2026
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease
Calum D Moulton1, C W P Hopkins, W Richard Bevan-Jones
1Institute of Psychiatry, King's College London.
Insights
Antidepressant treatment for Huntington's disease (HD) lacks sufficient evidence. Current research is inadequate to guide clinical practice or reduce suicide risk in HD patients with depression.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Depressive symptoms are prevalent in Huntington's disease (HD), significantly impacting patient quality of life and predicting suicidal ideation.
- A recent review of antidepressant therapies for HD is lacking, highlighting a gap in clinical guidance.
Purpose of the Study:
- To systematically review existing literature on antidepressant treatments for depressive symptoms in Huntington's disease (HD).
- To evaluate the efficacy and quality of evidence for various antidepressant interventions in the HD population.
Main Methods:
- A PRISMA systematic review methodology was employed, including controlled trials, uncontrolled trials, observational studies, and case series.
- Studies were included if they utilized a recognized antidepressant and measured depressive symptom changes with a validated psychiatric scale.
Main Results:
- Eleven studies involving 190 patients were analyzed, examining various agents including venlafaxine, fluoxetine, citalopram, atomoxetine, modafinil, lithium, and antipsychotics.
- No included study demonstrated adequate duration, sample size, or outcome measures; notably, no controlled trial in a depressed HD population yielded positive results.
Conclusions:
- There is insufficient evidence to guide the selection of antidepressant treatments for individuals with Huntington's disease (HD).
- Further rigorous research is essential to establish antidepressant efficacy in HD and explore depression treatment as a potential modifiable target for reducing the high suicide rate observed in this population.
Background:
Depressive symptoms are common in Huntington's disease (HD), profoundly affect quality of life, and predict suicidal ideation. However, no recent review of antidepressant treatment in HD has been published.
Methods:
We performed a PRISMA systematic review of HD studies, which used a recognized antidepressant and measured change in depressive symptoms using a validated psychiatric scale. Controlled trials, uncontrolled trials, observational studies, and case series were included.
Results:
Eleven studies were included, totalling 190 patients. One study examined venlafaxine, one fluoxetine, one citalopram, one atomoxetine, one modafinil, one lithium, and five antipsychotics. No studies were of adequate duration, size, or outcome, and no controlled trial in a depressed population produced a positive result.
Conclusions:
Inadequate evidence exists to guide antidepressant treatment in HD. Further research is needed to assess antidepressant efficacy and to examine whether treatment of depression represents a modifiable target for the high suicide rate in HD.
More Related Videos
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025